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AKTIVITI KARDIOVASKULAR VERNONIA AMYGDALINA 
 
ABSTRAK 
 
Beberapa ulasan mendokumenkan penggunaan etno-ubatan Vernonia 
amygdalina untuk rawatan hipertensi, tetapi penyiasatan secara saintifik masih terhad. 
Penyelidikan ini bertujuan untuk mengkaji kesan kardiovaskular in vitro dan in vivo 
dalam ekstrak daun V. amygdalina. Daun yang telah kering diekstrak dengan eter 
petroleum (VAPE), kloroform (VACE), metanol (VAME) dan air (VAWE) secara 
berturut-turut. Ekstrak tersebut dikaji dengan aktiviti vasorelaksan dalam gegelang 
aorta toraks tikus yang terpencil, aktiviti hipotensif terhadap tikus yang dibius, aktiviti 
anti-hipertensi, kekakuan arteri dan perubahan biokimia terhadap tikus hipertensi 
spontan (SHRs). Ekstrak yang paling berkesan dalam aktiviti vasorelaksan dan 
hipotensif seterusnya difraksinasi dan kajian mekanisme-mekanisme yang mungkin 
dijalani. Akhir sekali, analisis fitokimia V. amygdalina dijalankan dengan spektrometri 
jisim kromatografi gas dan kromatografi cecair prestasi tinggi. Hasil kajian 
menunjukkan bahawa semua ekstrak V. amygdalina mempunyai aktiviti vasorelaksan 
dan aktiviti hipotensif walaupun kepekatan berkesan untuk setiap ekstrak adalah 
berbeza; VACE menunjukkan aktiviti vasorelaksan yang paling berkesan manakala 
VAPE menunjukkan aktiviti hipotensf yang paling berkesan. Rawatan akut dan 
rawatan kronik (28 hari) oral 500 mg/kg ekstrak V. amygdalina menunjukkan kesan 
antihipertensi yang signifikan dan berkekalan. Fraksi heksana yang tidak larut 
daripada VACE (HI-VACE) menunjukkan kesan vasorelaksan yang tidak bersandar 
pada endotelium dan aktiviti antagonistik kalsium. Sebaliknya, 10 µM L-NAME, 10 
µM metilena biru, 10 µM indomethacin, 1 µM atropina, 1 µM propranolol,  1 µM 
xxiv 
 
prazosin tidak mengubah aktiviti vasorelaksan HI-VACE, menunjukkan bahawa 
laluan eNOS-NO-sGC-cGMP, pengeluaran prostanoid, reseptor muscarinic dan 
reseptor adrenergik tidak terlibat. Tiada fraksi VAPE menunjukkan kesan hipotensif 
yang ekuipoten atau lebih poten berbanding dengan asalnya. Kesan hipotensif daripada 
VAPE mungkin disebabkan oleh penghalang α-adrenergik dan β-adrenergik. 
Penurunan Ca2+ dalam sel yang disebabkan oleh penghalang saluran kalsium akan 
merencat tindakan yang teraruh oleh agonis α-adrenergik dan β-adrenergik. Oleh itu, 
VAPE berkemungkinan tinggi bertindak sebagai penghalang saluran kalsium. 
Sebatian yang terdapat dalam HI-VACE termasuk neofitadiena, asid linoleik dan asid 
oleik manakala dalam VAPE adalah 1-oktadekena, neophytadiene, asid palmitik, 
nonacosane, asid linoleik dan asid oleik. Kajian ini membekalkan asas farmakologi 
untuk penggunaan V. amygdalina dan mungkin lebih mendekati langkah fitoubat 
berasaskan bukti. 
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CARDIOVASCULAR ACTIVITIES OF VERNONIA AMYGDALINA 
 
ABSTRACT 
 
A few reviews on the ethno-medicinal use of Vernonia amygdalina for 
hypertension have been documented, but the scientific investigations are still very 
limited. The research was aimed to study the in vitro and in vivo cardiovascular effects 
of V. amygdalina leaf extracts. The dried leaf samples were successively extracted 
with petroleum ether (VAPE), chloroform (VACE), methanol (VAME) and water 
(VAWE). These extracts were examined for vasorelaxant activity in isolated rat 
thoracic aortic rings, hypotensive activity in anesthetized rats, anti-hypertensive 
activity, arterial stiffness and biochemical changes in spontaneous hypertensive rats 
(SHRs). The most effective vasorelaxant and hypotensive plant extracts were 
subjected for further fractionation and the possible mechanisms were elucidated. 
Lastly, phytochemical analysis of the most bioactive extract and fraction of V. 
amygdalina using gas chromatography mass spectrometry and high performance 
liquid chromatography were performed. The results showed that all V. amygdalina 
extracts evoke a vasodilating and hypotensive activity although the effective 
concentrations for each extract are different; VACE exhibit the most potent 
vasorelaxant activity whereas VAPE exhibit the most potent hypotensive activity. The 
acute and chronic (28 days) oral administration of 500 mg/kg V. amygdalina extracts 
induced a marked and sustained antihypertensive effects. Hexane-insoluble fraction of 
VACE (HI-VACE) exhibited an endothelium independent effect and calcium 
antagonistic activity. On the contrary, 10 µM L-NAME, 10 µM methylene blue, 10 
µM indomethacin, 1 µM atropine, 1 µM propranolol,  1 µM prazosin did not alter HI-
VACE-induced relaxation, indicating that eNOS-NO-sGC-cGMP pathways, 
xxvi 
 
prostanoids production, muscarinic receptor and  adrenergic receptor are not involved. 
None of the VAPE fraction showed equipotent or more potent hypotensive effect 
compared to their origin. The hypotensive effect of VAPE is possibly mediated as α-
adrenergic and β-adrenergic blocker. Reduction of intracellular Ca2+ by calcium 
channel blocker would inhibit the response induced by both α-adrenoceptors and β-
adrenoceptors agonists. Therefore, it is very likely that VAPE act as a calcium channel 
blocker. The compounds found in HI-VACE include neophytadiene, linoleic acid and 
oleic acid whereas in VAPE are 1-octadecene, neophytadiene, palmitic acid, 
nonacosane, linoleic acid and oleic acid. This study provides pharmacological basis 
for the use of V. amygdalina as anti-hypertensive agent and may be a step forward 
toward evidence-based phytomedicine. 
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CHAPTER I 
 
INTRODUCTION 
 
 
1.1 BACKGROUND  
The tide of hypertension is rising in Malaysia and all over the globe, thereby 
becoming an increasingly powerful threat to global health. According to the National 
Health and Morbidity Survey (NHMS) I, II and III in 1986, 1996 and 2006, the 
prevalence of hypertension in Malaysia was 14.4 %, 32.9 %, 42.6 % respectively for 
residents aged 30 years and above. Moreover, the most recent NHMS IV in 2011 has 
reported that the prevalence of hypertension in Malaysians aged 18 years and above 
was 32.7 % (5.8 million) and for aged 30 years and above was 43.5 %. These surveys 
show that the prevalence of hypertension in Malaysia has a relative increase of 30 % 
in 25 years from 1986 to the year 2011. Besides, only 35 % of Malaysian patients 
achieved blood pressure control (<140/90 mmHg) while on treatment (Clinical 
Practice Guideline on Management of Hypertension, 2013). Worldwide, 
approximately 40 % of adults aged 25 years and above had been diagnosed with 
hypertension in 2008. The number of people with the condition rose from 600 million 
in 1980 to 1 billion in 2008 (Danaei et al., 2011). In addition, it is estimated that by 
2025, up to 1.56 billion adults worldwide will be hypertensive (Kearney et al., 2005).  
The high prevalence of hypertension makes it a significant factor for mortality 
and morbidity. Hypertension is one of the most important contributors to heart disease 
and stroke – which together make up the world’s number one cause of premature death 
and disability (WHO, 2013). Globally, cardiovascular disease accounts for 
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approximately 17 million deaths a year, nearly one third of the total global deaths 
(WHO, 2008).  Of these, complications of hypertension account for 9.4 million deaths 
worldwide every year (Lim et al., 2012). Hypertension is responsible for at least 45% 
of deaths due to heart disease and 51% of deaths due to stroke (WHO, 2008). 
Individuals with hypertension are known to have a twofold higher risk of developing 
coronary artery disease (CAD), four times higher risk of congestive heart failure, and 
seven times higher risk of cerebrovascular disease and stroke compared to 
normotensive subjects. According to global estimates 62% of stroke, 49% of CAD, 
and 14% of other non-fatal cardiovascular disease (CVD) events are attributed to non-
optimal blood pressure (Lawes et al., 2006). Hypertension also increases the risk of 
conditions such as kidney failure and blindness (WHO, 2013). For all these 
complications, hypertension contributes substantially to the escalating costs of health 
care.  Even though it is easily diagnosed and treated, many people do not have access 
to basic health services, particularly in low- and middle-income countries, therefore, 
the disease burden caused by hypertension has increased over the past decade (Mendisi, 
2013). Recognizing the public health importance of reducing the global burden of heart 
disease and stroke, World Health Organization (WHO) is calling for intensified efforts 
to prevent and control hypertension on the World Health Day of 2013. 
In view of the growing number of hypertension and its life-threatening 
complications, coupled with the harsh side effects of costly modern pharmacological 
therapy resulting in patient non-compliance, the quest for alternatives which are 
relatively cost effective with minimal or no side effect is warranted. Natural products 
of plant origin have demonstrated promising potential. In fact, many ailments are 
known to be treated with herbal remedies throughout the history of mankind.  
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Representing an annual global market of US$ 60 billion every year, herbal 
medicines account for around 20 % of the overall drug market. According to WHO, 
up to 80 % of the population in Africa depends on traditional medicine for primary 
health care and in China, herbal medicines account for 30–50% of total medicinal 
consumption. In Europe, North America and other industrialized regions over 50% of 
the population have used complementary or alternative medicine at least once (WHO, 
2004). Today, researches are focusing on the discovery of new therapeutic substances 
of natural origin with possible low or no toxicity to human, animal and environment, 
based on ethno-medical and ethno-veterinary practices. The WHO (1993) supports the 
use of effective and safe remedies and accepts traditional medicine as a valuable and 
readily available resource of health care. During the period 2000-2005, 23 new drugs 
derived from natural sources were approved by the Food and Drug Administration 
(FDA) and introduced to the market, for cancer, cardiovascular, neurological, 
metabolic and immunological diseases, and genetic disorders (Chin et al., 2006).  
Several medicinal plants have been reported to have antihypertensive potential 
(Ameer, 2009; Globinmed, 2010; Kaur, 2013; Mashour et al., 1998; Tabassum and 
Ahmad, 2011; Yeap et al., 2010). An example of such plants is Vernonia amygdalina. 
A few studies have shown rationale in the use of V. amygdalina for the treatment of 
hypertension. Anti-hypertensive effect of V. amygdalina could be mediated through 
direct vasorelaxant mechanism from the findings of Taiwo and colleagues (2010). The 
inhibition of angiotensin converting enzyme (ACE), coupled with the antioxidant 
activities of V. amygdalina phenolic-rich extracts, could be another possible 
mechanism through which V. amygdalina exerts its anti-hypertensive property (Saliu 
et al., 2012). Furthermore, Ajibola and colleagues (2011) found that the polyphenolic 
fraction (chlorophyllic fraction) of the leaf extract of V. amygdalina displayed high 
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potency against both angiotensin converting enzyme (ACE) and renin as possible 
mechanisms of its antihypertensive potential.  
V. amygdalina occurs wild in most countries of tropical Africa (Grubben, 2004) 
and had been recently introduced into the Malaysia herbal armament.  The plant can 
be found along roadside or at home and commercial plantations in Malaysia 
(Atangwho et al., 2013; Globinmed, 2010; Yeap et al., 2010). This plant is well-known 
among Malaysian as a remedy for the management of diabetes mellitus and 
hypertension (Atangwho et al., 2013; Globinmed, 2010). Although V. amygdalina is 
commonly used ethno-medicinally for the management/treatment of hypertension 
(Gbolade, 2012; Karou et al., 2011; Lawal et al., 2010; Mensah et al., 2008; Saliu et 
al., 2012), the scientific investigations are still very few. The possible mechanism(s) 
of action of V. amygdalina extracts in alleviating hypertension in experimental animal 
models are lack of information. Moreover, the compound(s) in V. amygdalina 
responsible for the anti-hypertensive activity have not yet been identified. Hence, more 
scientific research such as mechanism study needs to be done to verify the 
effectiveness of V. amygdalina for its antihypertensive potential.  
On the other hands, Malaysia, being a rich of biodiversity and multi-racial 
country, has a rich heritage of various traditional medicine practices, each origins from 
different ethnic groups and many forms of traditional health care still practicing in 
spite of a remarkably modern rural health service (Ariff and Khoo, 2006). In 
accordance with the concomitant use of herbal medicines in the management of 
various illness such as hypertension, understanding of the V. amygdalina underlying 
mechanism of action in control of hypertension responsible for the anti-hypertensive 
activity would help to improve the care and health outcome of hypertensive patients. 
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1.2 RESEARCH OBJECTIVES  
1.2.1 General objective  
To study the in vitro and in vivo cardiovascular effects of Vernonia amygdalina leaf 
extracts. 
 
1.2.2 Specific objectives 
1. To perform the vasorelaxant and hypotensive activities guided fractionation of V. 
amygdalina leaf extracts.  
2. To elucidate the pharmacological mechanism(s) by which the most active plant   
extract exerts its proposed action by in vitro (vasorelaxant activity in isolated rat 
thoracic aortic rings) and in vivo (hypotensive activity in anesthetized Sprague 
Dawley rats) experimental methods.  
3.  To study the antihypertensive effect of V. amygdalina in conscious spontaneous 
hypertensive rats (SHRs).  
4.  To study the effect of V. amygdalina on arterial stiffness.  
5. To study the biochemical changes (kidney function tests, liver function tests and 
cardiac enzymes) of V. amygdalina -treated spontaneous hypertensive rats (SHRs). 
6. To perform a phytochemical analysis of the most bioactive extract and fraction of 
V. amygdalina using gas chromatography mass spectrometry (GCMS) and high 
performance liquid chromatography (HPLC). 
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CHAPTER II 
 
LITERATURE REVIEW 
 
 
2.1 THE CARDIOVASCULAR SYSTEM 
The cardiovascular system (cardio- = heart; vascular = blood vessels) consists 
of three interrelated components: the heart, blood vessels, and blood. Arterial pressure 
is generated by the force of blood pushing against the walls of blood vessels (arteries) 
as it is pumped by the heart. This arterial pressure serves as the driving force for blood 
flow to all organ systems. The relative distribution of blood flow to organs is regulated 
by the vascular resistance of the individual organ. Appropriate systemic arterial 
pressure is perhaps the single most important requirement for proper operation of the 
cardiovascular system (Klabunde, 2012; Mohrman and Heller, 2010; Tortora and 
Derrickson, 2009). 
 
2.1.1 Arteries and Arterioles 
The wall of a blood vessel are made up of three layers or tunics of different 
tissues: tunica interna (an epithelial inner lining), tunica media (a middle layer 
consisting of a smooth muscle and elastic connective tissue), and tunica externa (a 
connective tissue outer covering) (Figure 2.1). Modifications of this basic design 
account for the structural and functional differences among the various vessel types 
(Tortora and Derrickson, 2009).  
The wall of an artery has the three layers of a typical blood vessel, but has a 
thick muscular-to-elastic tunica media. Arteries are normally high compliance (stretch 
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easily) due to their plentiful elastic fibers and helps to conduct blood from the heart to 
various organ. Moreover, they act as a pressure reservoir for propelling blood onward 
during ventricular diastole.  
Arterioles, literally meaning small arteries, play a key role in regulating the 
flow of blood from arteries into the capillary networks of the body’s tissues by 
regulating resistance (opposition) to blood flow. Changes in the diameter of arterioles 
by sympathetic nerve supply in tunica externa, along with the actions of local chemical 
mediators, affect blood pressure. Vasoconstriction of arterioles increases blood 
pressure whereas vasodilation of arterioles decreases blood pressure (Mohrman and 
Heller, 2010; Tortora and Derrickson, 2009; Widmaier et al., 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Structure of an artery (Tortora and Derrickson, 2009).  
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2.1.2 Vascular Endothelium  
Endothelium is a monolayer of endothelial cells that lines the blood interface 
throughout the cardiovascular system, including the cardiac chambers. Endothelial 
cells play a wide variety of critical roles, including: (1) Regulating blood tissue 
exchange. (2) Paracrine secretions which include nitric oxide (NO), endothelium-
derived hyperpolarizing factor (EDHF), prostaglandin I2 (PGI2), and endothelin-1 
(ET-1) regulate vascular tone. (3) Inhibiting platelet aggregation (anti-thrombotic) 
primarily through biosynthesis of NO and PGI2. (4) Modulating leukocyte adhesion 
and transendothelial migration through the biosynthesis of NO and the expression of 
surface adhesion molecules. (5) Endothelial surface enzymes (eg: angiotensin 
converting enzyme) modify vasoactive peptides in the bloodstream. (6) Endothelium 
initiates new blood vessel formation. The roles of endothelium are thus many, diverse 
and vitally important (Mohrman and Heller, 2010; Klabunde, 2012; Levick, 2010; 
Pappano and Wier, 2013). 
 
2.1.2(a) Ion Channels 
Endothelial cells express a variety of ion channels. Most of them influence 
intracellular Ca2+ ion concentration which is a key regulator of endothelial function 
(Tran and Watanabe, 2006) such as nitric oxide production and the hyperpermeability 
of inflammation. Basal cytosolic Ca2+ concentration, 30-100 nM, is much lower than 
extracellular Ca2+ concentration, 1 mM, and can be increased five- to ten-fold (e.g. by 
histamine), partly by the influx of extracellular Ca2+ through ion channels, and partly 
by release of Ca2+ stored in the endoplasmic reticulum (Levick, 2010; Socha et al., 
2012).  
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Endothelial cells are not excitable, i.e. they cannot generate action potentials, 
because they do not express sufficient voltage-gated Na+ and Ca2+ channels. They do, 
however, have a regulated negative intracellular potential of -30 to -68mV, which is 
generated mainly by the outward diffusion of K+ ions through inward rectifier K+ 
channels (Kir) and calcium activated K
+ channels (KCa). Furthermore, the electrogenic 
3Na+-2K+ pump contributes about -8mV. Membrane potential magnitude is important 
because it affects the electrochemical force driving extracellular Ca2+ into the 
endothelial cell; abolition of the potential greatly attenuates Ca2+-mediated responses 
(Levick, 2010). Besides that, changes in endothelial membrane potential can be 
conducted through gap junctions to serve as a signal, as in ascending vasodilation 
(Levick, 2010; Sandow et al., 2006). 
 
2.1.2(a)(i) Ca2+-conducting Transient Receptor Potential Channels 
Although endothelium lacks voltage-gated Ca2+ channels, the surface 
membrane has two other types of Ca2+-conducting channel: receptor-operated 
channels and store-operated channels. When the cell is stimulated by an agonist, such 
as histamine, these Ca2+ channels are activated and raise the intracellular free Ca2+ 
concentration five- to ten-fold (Levick, 2010). 
Receptor-operated channels (ROCs) are cation-conducting channels that are 
activated via a biochemical cascade when an extracellular agent, the ‘agonist’, binds 
to its specific membrane receptor. Endothelial agonist include histamine, bradykinin, 
thrombin, serotonin, ATP and acetylcholine (Socha et al., 2012). The agonist receptor 
activated a G-protein, which activates the membrane-bound enzyme phospholipase C. 
Phospholipase C splits a phospholipid, phosphatidyl inositol biphosphate (PIP2), into 
diacylglycerol (DAG) and inositol triphosphate (IP3). The DAG activates the ROC ion 
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channel, and the IP3 releases a small store of Ca
2+ from the sarcoplasmic reticulum 
(Tran and Watanabe, 2006; Levick, 2010). ROCs are poorly selective cation channels 
that conduct Ca2+ and also some Na+ and K+. Since there is a large electrochemical 
gradient for Ca2+ influx, ROC activation raises cytosolic Ca2+ rapidly. The ROC 
constituent proteins were recently identified as members of the TRPC family (transient 
receptor potential, canonical subtype) (Levick, 2010). 
Store-operated channels (SOCs) are also Ca2+-conducting channels in the 
surface membrane, but their activation is associated with Ca2+ store release (Sinkins et 
al., 1998; Ong et al., 2002; Venkatachalam et al., 2002). There are two main types of 
SOC. Human endothelium expresses SOCs composed of TRPC1 protein (Groschner 
et al., 1998; Paria et al., 2003; Tiruppathi et al., 2002). These are low selectivity, 
cation-conducting channels that are activated by IP3 as it releases the endoplasmic 
reticulum store. A second type of SOC is composed of Orai1 proteins. This channel is 
exquisitely Ca2+-selective, and is activated by an endoplasmic reticulum proteins, 
ST1M1, following Ca2+ store release; so it is also called the CRAC channel (calcium-
release activated channel) (Prakriya and Lewis, 2015). SOC activation leads to an 
influx of extracellular Ca2+, called capacitative or store-operated Ca2+ entry (Prakriya 
and Lewis, 2015; Putney et al., 2001). This raises the free Ca2+ level, as well as 
restocking the SR store. SOCs are thought to be more abundant than ROCs in many 
types of endothelium (Levick, 2010). 
As a result of these multiple pathways, an agonist usually evokes a biphasic 
change in endothelial Ca2+ concentration. There is an initial high spike in free Ca2+ 
concentration, brought about by IP3-mediated store release and DAG-mediated ROC 
activation. This is followed by a lesser but more sustained Ca2+ elevation due to SOC 
activation (Levick, 2010). Endothelial cells may also possess stretch-activated 
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channels, which allow Ca2+ entry in response to shear stress (Kwan et al., 2003; Levick, 
2010; Resnick et al., 2003; Tseng et al., 1995). 
 
2.1.2(a)(ii) Calcium Activated K+ Channels (KCa) 
A rise in endothelial free Ca2+ activates a special type of K+ channels, the 
calcium-activated potassium channels KCa. This increases the membrane permeability 
to K+, leading to hyperpolarization. Hyperpolarization serve two functions. It increases 
the electrochemical force drawing extracellular Ca2+ into the cell; and it can be 
transmitted through myoendothelial gap junctions to induce arteriolar relaxation 
(Félétou and Vanhoutte, 2009; Levick, 2010). 
There are three subtypes of KCa channel: small conductance (SKCa), 
intermediate conductance (IKCa) and big conductance (BKCa). SKCa and IKCa 
expressed predominantly in endothelium, whereas BKCa occurs in vascular smooth 
muscle (Levick, 2010; Yang et al., 2012). SKCa and IKCa in the endothelium were 
found to be important for nitric oxide release (Absi et al., 2007; Brähler et al., 2009; 
Doughty et al., 1999; McNeish et al., 2006; Stankevicius et al., 2006). The channels 
are pharmacologically distinguishable: SKCa is blocked by apamin, a constituent of bee 
stings; IKCa and BKCa are blocked by charybdotoxin, a constituent of scorpion stings; 
and BKCa is blocked by iberiotoxin (Levick, 2010). 
  
2.1.2(b) The Discovery that Endothelium Modulates Vascular Tone 
The discovery that endothelium secretes vasoactive agents was reported 
relatively late. The role of the endothelium as a regulator of vascular tone began to 
emerge when Vane and colleagues discovered in 1976 that blood vessels secrete a 
vasodilator substance, prostacyclin (PGI2). A second endothelium-derived 
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vasodilating agent was discovered in 1980 by Furchgott and Zawadski, who noted that 
the vasodilation of large arteries by an acetylcholine analogue, carbachol, changed into 
vasoconstriction when the endothelial lining was rubbed away. It merged that agonists, 
such as acetylcholine, stimulate endothelium to secrete a vasodilator substance, nitric 
oxide. The vasodilator action of the endothelium-derived nitric oxides overrides the 
direct vasoconstrictor action of acetylcholine on arterial muscle. A third vasodilator, 
endothelium-derived hyperpolarizing factor (EDHF), was discovered in 1987 when it 
was realized that endothelium-dependent vasodilation continue to exist in small 
vessels after blocking nitric oxide and prostacyclin production. The response involves 
smooth muscle hyperpolarization. A fourth endothelial secretion, a vasoconstrictor 
peptide called endothelin, was discovered in 1989 by a Japanese group using molecular 
biology techniques. All four substances are released as they are produced, rather than 
being stored for later secretion (Levick, 2010). 
  
2.1.2(b)(i) Nitric oxide (NO)  
Nitric oxide is produced constitutively at a low basal rate which inhibits 
vascular tone and survives only seconds before degradation (Tousoulis et al., 2012). It 
is produced by a constitutively expressed enzyme, endothelial nitric oxide synthase, 
eNOS (NOS-III) which cleaves the nitrogen group from the amino acid L-arginine and 
combines it with oxygen to form NO (Cylwik et al., 2005; Moncada, 1993). Inactive 
analogues of arginine, such as nitroarginine methyl ester (NAME), compete with 
normal arginine for the eNOS binding site, and therefore act as eNOS blockers (Sainz 
et al., 2004). If NO synthesis is inhibited pharmacologically using eNOS blocker, 
vasoconstriction occurs in most vascular beds. NO is inactivated within seconds by 
two mechanisms: (1) NO reacts with a by-product of oxidative metabolism, the 
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superoxide anion O2
-, to form peroxynitrite, ONOO-. Peroxynitrite is then converted 
into ordinary nitrite (NO2
-) and nitrate (NO3
-) for excretion in the urine. (2) Some NO 
diffuses into the bloodstream, where its similarity to oxygen (O-O) causes it to bind to 
red cell haemoglobin (Levick, 2010). 
On the other hand, eNOS can be transiently stimulated to produce high levels 
of NO by environmental stimuli or agonists. Basal shear stress provides an important, 
tonic drive for NO production (Förstermann and Sessa, 2012; Joannides et al., 1995; 
Rubani et al., 1986). During exercise, increased blood flow in the arteries feeding the 
active skeletal muscles raises the shear stress and consequently NO production. This 
results in flow-induced vasodilation in large, conduit arteries supplying active muscle 
groups. The shear stress is probably transduced into a biochemical signal by the 
glycocalyx, since glycocalyx-degrading enzymes reduce NO production. Transduction 
activates the enzyme phosphatidyl inositol-3 kinase (PI3 kinase), leading to the 
activation of protein kinase B (akt) (Datta et al., 1999; Toker and Newton, 2000), 
which phosphorylates eNOS (Dimmeler et al., 1999; Futon et al., 1999). 
Phosphorylation render eNOS more sensitive to background Ca2+-calmodulin, the 
intracellular activator of eNOS (Levick, 2010). 
Besides that, eNOS activity can be enhanced by agonists such as acetylcholine 
and inflammatory mediators. Acetylcholine raise endothelial free Ca2+ concentration 
via the PLC-ROC/SOC pathway. Some of the Ca2+ binds to an intracellular Ca2+-
binding protein, calmodulin. The Ca2+-calmodulin complex enhances eNOS activity 
and hence NO production. Agonists that act in this way include bradykinin, thrombin, 
substance P, ATP, ADP, acetylcholine (via muscarinic M3 receptors), vasoactive 
intestinal polypeptide, insulin and in some tissues/species histamine (Tousoulis et al., 
2012; Levick, 2010). Several of these agents are released during inflammation, so NO 
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contributes to the characteristic redness (vasodilation) of inflamed tissue. NO causes 
vasodilation by two mechanisms: (1) Endothelial NO diffuses rapidly into neighboring 
vascular smooth muscle cells, where it binds to the haem group of a soluble enzyme, 
guanylyl cyclase. N-O is chemical cousin to O-O, oxygen, hence its high affinity for 
haem. The activated guanylyl cyclase catalyzes the production of cyclic guanosine 
monophosphate (cGMP) from guanosine triphosphate. The cGMP activates kinases 
(enzymes that phosphorylate other proteins to alter their activity) that produce vascular 
relaxation (Giles et al., 2012). (2) High concentrations of NO directly activate big 
conductance KCa channels (BKCa) in the smooth muscle membrane. This 
hyperpolarizes the smooth muscle, leading to vascular relaxation. The drug 
nitroprusside also increases cGMP, causing vasodilation. Nitroprusside acts directly 
on the vascular smooth muscle; its action is not endothelially mediated (Levick, 2010). 
Nitric oxide (NO) is soluble in both lipid and water, so it diffuses freely from 
the endothelium into the neighboring vascular smooth muscle and bloodstream, with 
multiple local effects (Förstermann and Sessa, 2012; Hermann et al., 2006; Levick, 
2010; Klabunde, 2012):  
1) NO lowers vascular tone in veins, and in large muscular arteries, such as the 
coronary artery. NO also dilates small resistance vessels, though endothelial derived 
hyperpolarizing factor (EDHF) is relatively more important in these vessels.  
2) NO contributes to gap formation in venules during inflammation. 
3) NO inhibits vascular myocytes proliferation, a component of atheroma. 
4) NO inhibits platelet aggregation and thus protects blood vessels from thrombosis, 
5) NO inhibits the transcription of leukocyte-binding adhesion molecules, such as 
endothelial vascular cell adhesion molecule (VCAM), involved in attaching leukocytes 
to the endothelial surface. 
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The inhibition of smooth muscle proliferation, platelet activation and 
leukocytes adhesion by NO are all anti-atheroma actions, and reduced NO availability 
is thought to contribute to atheroma formation. Plasma-derived cholesterol and fibrin 
trapped between the endothelium and tunica media, leading to the formation of 
atheromatous plaque (Levick, 2010; Klabunde, 2012). 
 
2.1.2(b)(ii) Endothelium-derived Hyperpolarizing Factors (EDHF) 
NO exerts its main physiological effects in large vessels, where eNOS is 
abundant. If NO and prostacyclin production are blocked in small arteries and 
arterioles, agonists such as acetylcholine and bradykinin still evoke endothelium-
dependent dilatation, which is mediated by smooth muscle hyperpolarization (Edwards 
et al., 2010; Félétou and Vanhoutte, 2009). Also, in some tissues saline washed through 
agonist-stimulated vessels picks up a chemical that can hyperpolarize isolated vascular 
muscle – an ‘endothelium-derived hyperpolarizing factor’, EDHF. 
The stimuli for EDHF production include the classical parasympathetic 
transmitter acetylcholine, inflammatory agents such as bradykinin, and possibly shear 
stress. The roles of EDHF are thought to be: (1) To help increase blood flow to 
exercising muscle, by dilating small, feed arteries. (2) To contribute to the cholinergic 
vasodilation of small resistance vessels in certain tissues with a cholinergic autonomic 
innervation. (3) To contribute to the vasodilation of inflammation (Levick, 2010). 
The identity of EDHF is controversial. Although endothelium-derived 
hyperpolarization can indeed be brought about by release, chemical factor(s) in some 
tissues, it can also be brought about by direct, electrical coupling between the 
endothelium and vascular muscle. Electrical transmission may be the primary 
hyperpolarizing mechanism, with released, soluble EDHFs serving to boost the 
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myocyte hyperpolarization (Edwards et al., 2010; Félétou and Vanhoutte, 2009; Giles 
et al., 2012). 
Direct electrical transmission of endothelial hyperpolarization to vascular 
myocyte has been demonstrated in arterioles and small arteries (diameter ~ 100 µm), 
where myoendothelial gap junctions are abundant. When an agonist raises the 
endothelial free Ca2+ concentration, the activated small conductance KCa channel 
(SKCa) and intermediate conductance KCa channel (IKCa) hyperpolarize the endothelial 
cell. The endothelial hyperpolarization then spreads through the myoendothelial 
(heterocellular) gap junctions to hyperpolarize and relax the vascular myocytes 
(Edwards et al., 2010; Félétou and Vanhoutte, 2009). This form of ‘EDHF’ is inhibited 
by gap junctions blockers, and by apamin and charybotoxin, the blockers of endothelial 
SKCa and IKCa channels (Levick, 2010). 
The endothelial cell also releases soluble factors (NO, prostacyclin, H2O2, and 
epoxyeicosatrienoic acid) that cause hyperpolarization of vascular smooth muscle by 
activation of large conductance KCa channels (BKCa). This action moves the membrane 
potential farther from the threshold at which Ca2+ entry occurs.  In small coronary, 
renal and skeletal muscle arteries, epoxyeicosatrienoic acid (EET) may be an 
additional EDHF. In these vessels, the agonist bradykinin activates endothelial 
phospholipase A2, which generates arachidonic acid. Arachidonic acid is converted by 
endothelial cytochrome P450 epoxygenase to diffusible EET. Myocyte EET receptors 
trigger a pathway that activates myocyte BKCa channels, leading to hyperpolarization 
and vasodilation. Additional candidate EDHF factors are hydrogen peroxide and c-
natriuretic peptide. Also, activated endothelial SKCa and IKCa channels release K
+ ions 
into the interstitial spaces around neighboring vascular myocytes. The rise in 
extracellular K+ reinforces myocyte hyperpolarization, by stimulating the myocytes 
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3Na+-2K+ pump and by activating myocyte Kir channels. EDHF becomes an 
increasingly important as a vasodilator in the microcirculation as vessel radius 
decreases (Edwards et al., 2010; Félétou and Vanhoutte, 2009; Giles et al., 2012; 
Levick, 2010; Pappano and Wier, 2013). 
 
2.1.2(b)(iii) Prostacyclin (PGI2) 
Like NO, prostacyclin (prostaglandin I2, PGI2) causes vasodilation and inhibits 
platelet aggregation, both of which are induced by the formation of cAMP (Kawabe et 
al., 2010; Majed and Khalil, 2012). It is produced by endothelium constitutively and 
also in response to agonists, such as thrombin. Phospholipase A2 converts membrane 
phospholipids into the unsaturated fatty acid, arachidonic acid. The arachidonic acid 
is then converted by cyclo-oxygenases into prostacyclin (Kawabe et al., 2010; Majed 
and Khalil, 2012). Prostacyclin production is greatly increased in inflammation and 
contributes to the associated vasodilation. It also contributes to the cutaneous 
vasodilation associated with sweating (Klabunde, 2012; Levick, 2010; Pappano and 
Wier, 2013). 
 
2.1.2(b)(iv) Endothelins 
The endothelins are a family of peptides related to the snake venom sarafotoxin. 
Endothelin-1 (ET-1), the main isoform secreted by the endothelium (Battistini et al., 
1993), causes a powerful, unusually sustained vasoconstriction, lasting 2-3 hours. ET-
l is a potent vasoconstrictor for substance that is synthesized from an intracellular 
precursor by endothelin-converting enzyme (ECE) found on the endothelial cell 
membrane (Xu et al., 1994).  ET-1 leaves the endothelial cell and can bind primarily 
to receptors (ETA) on vascular smooth muscle (Huggins et al., 1993), which are 
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coupled via a Gq-protein to the myocyte phospholipase C-IP3 system (Simonson and 
Dunn, 1990). The resulting rise in myocyte Ca2+ triggers vasoconstriction (Wagner et 
al., 1992). Over a longer time scale, endothelin also stimulates vascular and cardiac 
myocyte proliferation. ET-1 can also bind to a second type of receptor (ETB) located 
on the vascular endothelium (Huggins et al., 1993) that stimulates nitric oxide and 
prostacyclin synthesis and release (Sakurai et al., 1990), which act as negative 
feedback mechanisms to counteract the ETA-mediated vasoconstrictor effects of ET-
1. 
Endothelin is produced continuously and makes a small contribution to basal 
vascular tone in humans. Its production can be increased by hypoxia, angiotensin II, 
vasopressin, thrombin, cytokines, reactive oxygen species, and shearing forces. ET-1 
release is inhibited by nitric oxide, as well as by prostacyclin and atrial natriuretic 
peptide. Plasma endothelin levels are raised in pre-eclamptic toxaemia (the 
hypertension of pregnancy) (Ajne et al., 2003) and heart failure (Murphy et al., 2010; 
Neuhold et al., 2010). Endothelin also contributes to cerebral artery vasospasm in 
patients with haemorrhagic strokes. Some forms of hypertension (e.g., pulmonary 
artery hypertension) appear to involve ET-1 and are treated with ET-1 receptor 
blockers (Klabunde, 2012; Levick, 2010; Pappano and Wier, 2013). 
 
2.1.3 Vascular Smooth Muscle Cells 
The tunica media of arteries, arterioles, venules and veins consists mainly of 
vascular smooth muscle cells (vascular myocytes). They are responsible for the control 
of total peripheral resistance, arterial and venous tone, and the distribution of blood 
flow throughout the body (Levick, 2010).  
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2.1.3(a) Molecular mechanism regulating  Ca2+-dependent contraction in smooth 
muscle 
In smooth muscle, the interaction between myosin and actin, which leads to 
vascular contraction depends primarily on cytoplasmic Ca2+ concentration (Berridge, 
2008). A rise in cystosolic Ca2+ concentration causes the formation of Ca2+-calmodulin 
complex; calmodulin is a cytoplasmic protein presents in high abundance in smooth 
muscle cells, which binds 4 Ca2+ (Vogel, 1994). The Ca2+-calmodulin complex 
activates enzymes, myosin-light chain kinase (MLCK) (Kamm and Stull, 2001). The 
20-kDa regulatory light chain (MLC20) is a component of the myosin heads involved 
in cross-bridge formation with actin filaments, and vascular myosin only forms cross-
bridges when the MLC20 is phosphorylates. MLCK transfers a phosphate groups from 
ATP to the MLC20, enabling myosin head to form a cross-bridge with actin (Figure 
2.2) (Allen and Walsh, 1994; Hirano, 2007; Somlyo and Somlyo, 2003). 
The phosphate group can be removed by the enzyme, myosin light chain 
phosphatase (MLCP). When intracellular Ca2+ concentration falls, MLCK activity 
declines and the competing MLCP dominates, dephosphorylating the myosin. Since 
dephosphorylated myosin cannot form new cross-bridges, the MLCP in effect turns 
off the myosin motor. As existing cross-bridges detach, new ones cannot forms, so the 
myocytes relax, leading to vasodilation (Hirano, 2007; Somlyo and Somlyo, 2003). 
Increased MLCP activation may explain cases of vascular relaxation with little fall on 
cytosolic Ca2+ concentration, e.g. hypoxic vasodilation.  
The cytoplasmic Ca2+ concentration, and thus MLCK activity, is determined 
by the summation of the Ca2+ that enters the cytosol (influx) and that leaving the 
cytosol (efflux). Ca2+ enters the cytosol in two ways: (1) from the extracellular space, 
via influx through voltage-operated calcium channels (typically L-type, activated by 
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depolarization (Walsh, 2011). The voltage–sensitive Ca2+ channels have a low but 
finite open-state probability under basal conditions, allowing small extracellular Ca2+ 
influx that  contributes to basal tone), receptor-operated calcium channels (ROCs, 
activated after the action of agonists on membrane receptors), and store-operated 
calcium channels (activated after depletion of sarcoplasmic reticulum Ca2+ stores), and 
(2) stored Ca2+  is released from the sarcoplasmic reticulum (SR) via activation of 
either ryanodine receptor channels, RyRs or inositol-1,4,5 triphosphate (IP3) receptor 
channels (IP3-stimulated) located on the SR (Hill-Eubanks et al., 2011). Ca
2+ ions leave 
the cytosol via ATP-driven calcium transporters (i.e., Ca2+ pumps) located on both the 
SR (termed SERCAs) and plasma membrane (termed PMCAs) as well as activation of 
the Na+/Ca2+ exchangers on the plasma membrane as in cardiac muscle. SR uptake is 
called Ca2+ sequestration and extracellular transfer is called Ca2+ expulsion. Due to the 
small but continuous influx of Ca2+ through Ca2+ channels in the basal state, the 
sarcolemmal Ca2+ pumps have to expel Ca2+ continuously, otherwise, Ca2+ would 
accumulate in the cell (Klabunde, 2012; Levick, 2010; Pappano and Wier, 2013).  
 
Figure 2.2 Regulation of vascular smooth muscle contraction by myosin light chain 
kinase (MLCK). ATP, adenosine triphosphate; cAMP, cyclic adenosine 
monophosphate; MLC, myosin light chains; Pi, phosphate group; SR, sarcoplasmic 
reticulum (Klabunde, 2012). 
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2.1.3(b) Two Phases of Vasoconstriction 
If the vessel wall is loaded with a Ca2+-sensitive fluorescent dye, it is found 
that the cytosolic free Ca2+ concentration exhibits two distinct phases following 
stimulation. In the initial, transient phase, there is a rapid increase in cytosolic Ca2+ 
concentration, from ~0.1 µM to ~ 1 µM. This occurs synchronously in all the myocytes 
throughout the vessel wall, and is followed almost immediately by a rise in tension. In 
the second, tonic phase, starting 30-60 s later, the average cytosolic [Ca2+] in the vessel 
wall retreats to a lower but still suprabasal level; yet the force of contraction is well 
maintained. During the second phase, individual myocytes may exhibit intermittent 
asynchronous Ca2+ waves, especially in small artery myocytes with a low contractile 
tone; second phase Ca2+ tend to be more stable in vessels with a  high basal tone 
(Levick, 2010). 
 
2.1.3(b)(i)The Initial Phase  
The initial large increase in myocyte free Ca2+ results from the release of stored 
Ca2+ from the SR, particularly in large arteries, aided by an influx of extracellular Ca2+, 
particularly in small arteries and arterioles. In large arteries, Ca2+ store release accounts 
for most of the initial cytosolic Ca2+ transient, because the SR is well developed. Store 
discharge is triggered chiefly by receptor-induced IP3 production. Store replenishment 
is brought about by an influx of extracellular Ca2+ ions through the store-operated TRP 
channels in the adjacent sarcolemma (capacitative Ca2+ entry). In smaller, resistance 
arteries/arterioles, extracellular Ca2+ influx is more important, because small resistance 
vessels tend to have scanty SR but abundant VSCCs. The VSCCs are activated by 
depolarization, which is brought about by icat and iCl(Ca). Extracellular Ca
2+ influx 
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through the activated VSCCs, and also through ROCs, raises the cytosolic Ca2+ 
concentration. 
To summarize the initial 30-60 s phase of vasoconstriction, the agonist-
receptor complex activates the PLCβ-IP3-DAG pathway (Figure 2.3). IP3 releases 
stored Ca2+, which raises cytosolic Ca2+ and activates depolarizing current iCl(Ca). The 
DAG activates depolarizing current icat. The depolarization by icat and iCl(Ca) increases 
the open-state probability of sarcolemmal VSCCs, admitting extracellular Ca2+. DAG 
also activates sarcolemmal ROCs, that admit extracellular Ca2+. A 4 Ca2+-calmodulin 
complex then activates MLCK, which phosphorylates the myosin light chains, 
enabling the myosin heads to form crossbridges with the actin filament. Crossbridge 
flexion then generates shortening and tension (Levick, 2010). 
 
2.1.3(b)(ii) The Second Phase 
During the tonic phase, the mean cytosolic Ca2+ concentration, averaged across 
the whole tunica media, drops below the transient peak value; and in some vessels the 
individual myocytes develop intermittent Ca2+ waves. Each Ca2+ wave is generated by 
SR store discharge by IP3. Since the sarcolemmal pumps expel some Ca
2+ during each 
wave, extracellular Ca2+ influx through VSCCs and cat-SOCs is needed to recharge 
the stores. The importance of extracellular Ca2+ influx during tonic contraction is 
demonstrated by the relaxation induced by nifedipine and cat-SOC blockers. 
During the tonic phase, vasoconstriction is well maintained despite a fall in 
mean cytosolic [Ca2+]. Therefore, some additional mechanism must come into play. 
This mechanism is Ca2+ sensitization - a given level of Ca2+ has an increased contractile 
effect during the tonic phase. Ca2+ sensitization is brought about by kinases that are 
activated by the G protein-coupled receptors. Kinases are a large family of enzymes 
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that phosphorylate other proteins to change their activity. The kinase chiefly 
responsible for Ca2+ sensitization is rhoA kinase. Agonist-receptor complexes coupled 
to G12 protein activate rhoA, a monomeric GTPase that activates rhoA kinase. RhoA 
kinase inhibits myosin light chain phosphatase, the enzyme responsible for 
dephosphorylating the myosin head and turning off the myosin motor. This shifts the 
dynamic balance between MLC kinase and MLC phosphatase in favour of 
phosphorylation, despite a fall in Ca2+-calmodulin.  
Ca2+ sensitization is also promoted in some vessels by protein kinase C-α 
(PKCα), which is activated by DAG and cytosolic Ca2+. PKC activates CPI-17 protein, 
which, like rhoA kinase, inhibits myosin light chain phosphatase. PKC also triggers a 
MAP kinase pathway that phosphorylates caldesmon, a regulatory protein on the actin 
filament facilitating crossbridge formation. This may explain why adrenergic-
stimulated tone is maintained in some vessels despite a fall in myosin light chain 
phosphorylation (Levick, 2010). 
 
2.1.3(c) Mechanisms for relaxation 
A major function of blood vessels, especially resistance vessels, is to dilate, so 
as to raise blood flow to exercising muscle, myocardium, etc. Vasodilation is not an 
active process; it is simply a reduction of tonic contractile tension, i.e. a relaxation, 
and it can be brought about by four mechanisms: (1) hyperpolarization, (2) the 
adenylyl cyclase-cAMP-protein kinase A (PKA) pathway, (3) the guanylyl cyclase-
cGMP-protein kinase G (PKG) pathway, and (4) desensitization to Ca2+. 
The first three mechanisms produce vasodilation by reducing the cytosolic Ca2+ 
concentration, which reduces MLC kinase activity. This allows the constitutive 
background MLC phosphatase activity to predominate and turn off the myosin motor. 
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The fourth vasodilator mechanism, desensitization to Ca2+, produces vascular 
relaxation despite little fall in cytosolic Ca2+ concentration (Levick, 2010; Mohrman 
and Heller, 2010). 
 
2.1.3(c)(i) Hyperpolarization  
Hyperpolarization closes VSCCs, leading to a fall in cytosolic free [Ca2+] and 
vasodilation. Examples are as follows: (1) Skeletal muscle contraction, myocardial 
contraction and brain activity raise the K+ ion concentration in the local interstitial 
fluid. Extravascular K+ increases vascular Kir activity, leading to hyperpolarization and 
vasodilation. This is one of several mechanisms that match blood flow to tissue 
metabolic activity (Félétou, 2011). (2) Endothelium-derived hyperpolarization factors 
(EDHF) elicit vasodilation through myocyte hyperpolarization. In feed arteries, 
conducted vasodilation is due to the conduction of endothelial hyperpolarization into 
myocytes through myoendothelial gap junctions (Edwards et al., 2010; Félétou and 
Vanhoutte, 2009). (3) Hypoxia, if severe, can activate myocyte KATP channels, leading 
to hyperpolarization, reduced cytosolic [Ca2+] and hypoxic vasodilation (Kalsner, 
1995). In many arteries, however, Ca2+ desensitization is the main mechanism 
underlying hypoxic vasodilation, and there is little reduction in cytosolic [Ca2+]. KATP-
activating drugs, such as diazoxide, pinacidil and cromakalim, elicit vasodilation 
through myocyte hyperpolarization. (4) Sensory nerve neuropeptides, such as 
calcitonin gene-related peptide and vasoactive intestinal polypeptide, are released 
during inflammation, and contribute to the vasodilation of inflammation by causing 
hyperpolarization (Levick, 2010; Mohrman and Heller, 2010). 
 
 
